2112 Federal Register / Vol. 80, No. 10 / Thursday, January 15, 2015 / Notices 

• HHS Reference No. E–042–2012/0– 

US–06—U.S. Patent Application No. 14/ 

370,140 filed July 1, 2014. 

• HHS Reference No. E–201–2012/0– 

PCT–02—PCT Application No. PCT/

US2013/069796 filed November 13, 

2013, which published as WO 2014/

078350 on May 22, 2014. 

Licensing Contact: Surekha Vathyam, 

Ph.D.; 301–435–4076; vathyams@

mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, 

Molecular Targets Development 

Program, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize aza-englerin analogues as 

cancer inhibitors. For collaboration 

opportunities, please contact John D. 

Hewes, Ph.D. at john.hewes@nih.gov. 

Nicotine Conjugate Treatment for 

Parkinson’s Disease 

Description of Technology: It has been 

known since 1959 that tobacco use has 

protective effects against Parkinson’s 

disease. However, efforts to turn that 

knowledge into a safe and effective 

treatment, divorced from tobacco use, 

have had little success. An inventor at 

FDA now has in vitro evidence that 

nicotine promotes a protein clearance 

system, thereby halting Parkinson’s 

disease progression. In addition to using 

nicotine as the treatment, the inventor 

has created a coated conjugate of 

nicotine and nanoceria. This conjugate 

not only harnesses the power of nicotine 

but also takes advantage of the antioxidant effect of the nanoceria to reduce 

the oxidant environment, which is also 

a major mechanism of neuronal damage 

in Parkinson’s disease. 

Potential Commercial Applications: 

Treatment for Parkinson’s disease. 

Competitive Advantages: Improved 

mechanism to use nicotine as a 

treatment. 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventor: Syed Z. Imam (FDA). 

Intellectual Property: HHS Reference 

No. E–016–2014/0—U.S. Provisional 

Application No. 62/010,033 filed June 

10, 2014. 

Licensing Contact: Jaime M. Greene, 

M.S.; 301–435–5559; greenejaime@

mail.nih.gov. 

Collaborative Research Opportunity: 

The FDA National Center for 

Toxicological Research, Division of 

Neurotoxicology, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize A Nicotine-NanoCeria 

Conjugate named NIC–NANO for 

treatment of Parkinson’s disease. For 

collaboration opportunities, please 

contact Syed Z Imam at syed.imam@

fda.hhs.gov. 

cGAP–PNA Multivalent Ligand Display 

at the Nanoscale 

Description of Technology: Scientists 

at the NIH are developing new types of 

peptide nucleic acids (PNAs) that 

maintain aqueous solubility at longer 

lengths. This new type of PNA is called 

‘‘cGAP–PNA’’ because it contains a 

sequence complementary to the L–PNA 

sequence, which is a PNA with one or 

more gamma-sidechains that displays a 

ligand. The investigators have 

synthesized cGAP–PNAs that are 60 

nucleobases long that can support the 

assembly of 5 complementary L–PNAs 

(each with 12 nucleobases) that bear 

specific ligands. This platform can 

replace more traditional multivalent 

scaffolds, such as dendrimers and gold 

nanoparticles. 

Potential Commercial Applications: 

Multivalent ligand display. 

Competitive Advantages: 

• Decreased hydrophobicity 

• Increased water solubility 

• Can be used at very long lengths 

• More stable and resistant to 

degradation than existing PNAs 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventors: Daniel H. Appella, Andrew 

V. Dix, Ethan A. Englund, Kara M. 

George Rosenker (all of NIDDK). 

Publication: Dix A, et al. 

Programmable nanoscaffolds that 

control ligand display to a G-proteincoupled receptor in membranes to allow 

dissection of multivalent effects. J Am 

Chem Soc. 2014 Sep 3;136(35):12296– 

303. [PMID 25116377]. 

Intellectual Property: HHS Reference 

No. E–761–2013/0—U.S. Provisional 

Application No. 61/929,893 filed 

January 21, 2014. 

Related Technologies: 

• HHS Reference No. E–308–2006/

3—U.S. Application No. 13/592,490 

filed August 23, 2012. 

• HHS Reference No. E–129–2010/

0—EP Application No. 11721899.0 filed 

May 11, 2011; U.S. Application No. 13/ 

697,123 filed November 9, 2012. 

Licensing Contact: Charlene S. 

Maddox, Ph.D.; 301–435–4689; 

charlene.maddox@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize this 

technology. For collaboration 

opportunities, please contact Marguerite 

Miller at Marguerite.Miller@nih.gov or 

301–496–9003. 

Dated: January 9, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–00535 Filed 1–14–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Closure Devices for Transcaval Access to the 

Abdominal Aorta. 

Date: February 6, 2015. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Room 7185, Bethesda, MD 

20892, (Telephone Conference Call). 

Contact Person: Kristen Page, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7185, Bethesda, MD 20892, 301–435–0725, 

kristen.page@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: January 8, 2015. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–00497 Filed 1–14–15; 8:45 am] 

BILLING CODE 4140–01–P 


rljohnson on DSK3VPTVN1PROD with NOTICES